SCHEMBL3597532

SCHEMBL3597532

CCOC(=O)C(O)(c1cn(C)c2c(NS(=O)(=O)c3ccc(C)cc3)cccc12)C(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
GLA P06280 1/20 0.46
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
BRD4 O60885 2/20 0.39
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 2/20 0.39
ALOX15 P16050 2/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 3/20 0.39
TSHR P16473 2/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591270 0.88 GLA (0.47) LMNAGLAMAPTNPSR1HTT
SCHEMBL3600722 0.86 LMNA (0.44) LMNAGLAMAPTNPSR1RXFP1
SCHEMBL3600074 0.81 LMNA (0.47) LMNAMAPTNPSR1RXFP1FFAR4
SCHEMBL3589822 0.81 MAPT (0.47) LMNAGLAMAPTNPSR1FFAR4
SCHEMBL3591470 0.76 GLA (0.47) LMNAGLAMAPTNPSR1ALDH1A1
SCHEMBL13254019 0.75 GLA (0.75) LMNAGLANPSR1ALDH1A1HTT
SCHEMBL3596257 0.74 GLA (0.39) LMNAGLATSHRHSD17B10KDM4E
SCHEMBL3604598 0.72 MAPT (0.43) LMNAMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL3592376 0.72 MAPT (0.46) LMNAMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL3597954 0.71 GLA (0.50) GLAMAPTNPSR1RECQLGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 LMNA 4335/4885GLA 3982/4885MAPT 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.